期刊文献+

广泛期小细胞肺癌转移状态对生存的影响

Effect of extensive small cell lung cancer metastasis on patient's survival
原文传递
导出
摘要 目的回顾性分析广泛期小细胞肺癌患者转移状态对其生存的影响,以指导预后评估。方法 2003年1月至2008年12月收治134例广泛期小细胞肺癌患者,采用Kaplan-Meier法及Cox回归模式来分析患者一般情况、局部受侵情况、远处转移部位、多器官联合转移状态、转移病灶数目等因素与生存的关系。结果单因素、多因素生存分析远处转移部位与生存密切相关:肝、骨髓转移者生存期最短,中位生存期5个月;而肺转移者中位生存期最长8个月,统计学分析有明显差异(P<0.05);患者一般情况如性别、年龄、一般状况评分、局部受侵情况如有无胸水、心包积液及上腔静脉压迫综合征等及多器官联合转移状态、转移病灶数目等因素与生存期无关(P>0.05)。结论本组病例显示远处转移部位与广泛期小细胞肺癌患者生存相关。 Objective To retrospectively analyze the effect of extensive small cell lung cancer (SCLC) metastasis on survival of SCLC patients. Methods Kaplan-Meier method and Cox regression were used to analyze the relation between general condition,local invasion,distal metastasis,multiple organ metastasis,metastatic foci and survival of 134 patients with extensive SCLC metastasis,admitted to hospital from January 2003 to December 2008. Results Univariate analysis and multivariate analysis showed that the distal organ metastasis was closely related with the survival of patients with extensive SCLC metastasis (P0.05). The survival time of SCLC patients with liver and kidney metastasis was the shortest with a median survival time (MST) of only 5 month (RR=0.423),while the MST of those with lung metastasis was 8 months (RR=-0.450,P0.05). The survival of SCLC patients was not related with their sex,age and general condition,local invasion (including pleural effusion and pericardial effusion),superior vena cava compression syndrome,multiple organ metastasis,and metastatic foci. Conclusion The survival of SCLC patients is related with distal metastatic organs but not with the general condition,local invasion,multiple organ metastasis,and metastatic foci.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2010年第17期1861-1864,共4页 Journal of Third Military Medical University
关键词 广泛期 小细胞肺癌 转移 预后 extensive stage small cell lung cancer metastasis prognosis
  • 相关文献

参考文献12

  • 1Yip D, Harper P G. Predictive and prognostic factors in small cell lung cancer: current status[J].Lung Cancer, 2000, 28 (3) : 173 - 185.
  • 2Pires N F, Morais A, Queiroga H. Superior vena cava syndrome as tumonr presentation[J]. Rev Port Pneumol, 2010, 16( 1 ) : 73 -88.
  • 3宋丽华,宋现让,张锡芹,齐洁琳,李秀菊,田禾,步兵.小细胞肺癌患者预后因素分析[J].中华肿瘤杂志,2004,26(7):413-416. 被引量:23
  • 4Junker K, Wiethege T, Muller K M. Pathology of small-cell lung cancer[J]. J Cancer Res Clin Oncol, 2000, 126(7) : 361 -368.
  • 5Zakowski M F. Pathology of small cell carcinoma of the lung [ J ]. Semin Oncol, 2003, 30(1): 3-8.
  • 6Pisick E, Jagadeesh S, Salgia R. Small cell lung cancer: from molecular biology to novel therapeutics[ J]. J Exp Ther Oncol , 2003, 3 (6) : 305 -318.
  • 7李勇,张湘茹,孙燕.小细胞肺癌患者预后的多因素分析[J].中国肺癌杂志,2006,9(6):525-529. 被引量:19
  • 8Okuma Y, Hosomi Y, Kitamura K, et al. Choroidal metastasis in a patient with small cell lung cancer discovered during treatment with chemotherapy[J]. Int J Clin Oncol, 2009, 14(6) : 541 -544.
  • 9Chen G, Huynh M, Chen A, et al. Chemotherapy for brain metastases in small-cell lung cancer[J]. Clin Lung Cancer, 2008, 9 (1) : 35 -38.
  • 10Tas F, Aydiner A, Topuz E, et al. Factors influencing the distribution of metastases and survival in extensive disease small cell lung cancer[J]. Acta Oncol, 1999, 38(8) : 1011 -1015.

二级参考文献16

  • 1Yip D, Harper PG. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer, 2000,28:173-185.
  • 2Lagacos SW. Prognostic factors for patients with inoperable lung cancer. In: Straus MJ. Lung cancer, clinical diagnosis and treatment. 2nd.New York: Gruns &amp; Stratton Inc, 1983. 256-258.
  • 3Wolf M, Holle R, Hans K, et al. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer, 1991,63:986-992.
  • 4Jorgensen LG, Osterlind K, Genolla J, et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer, 1996,74:463-467.
  • 5Hatzakis KD, Froudarakis ME, Bouros D, et al. Prognostic value of serum tumor markers in patients with lung cancer. Respiration, 2002,69:25-29.
  • 6Shibayama T, Ueoka H, Nishii K, et al. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC).Lung Cancer, 2001,32:61-69.
  • 7Naumnik W, Chyczewska E. The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer. Folia Histochem Cytobiol, 2001,39:185-186.
  • 8Orditura M, De Vita F, Roscigno A, et al. Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with solid tumors. Int J Mol Med, 1998,2:75-79.
  • 9Bunn PA Jr, Lichter AS, Makueh RW, et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. A prospective, randomized trial. Ann Intern Med,1987,106(5):655-662.
  • 10Navada S, Lai P, Schwartz AG, et al. Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology,and End-Results (SEER) database. Proc Am Soc Clin Oncol,2006,24:384S(7082).

共引文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部